Supernus Pharmaceuticals Stock

Supernus Pharmaceuticals Dividend 2024

Supernus Pharmaceuticals Dividend

0 USD

Supernus Pharmaceuticals Dividend yield

Ticker

SUPN

ISIN

US8684591089

WKN

A1JX3U

How much dividend does Supernus Pharmaceuticals 2024 pay?

According to the latest status from October 2024, Supernus Pharmaceuticals paid a total of 0 USD per share in dividends within the last 12 months. With the current Supernus Pharmaceuticals price of 32.02 USD, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.

=

Historical Supernus Pharmaceuticals Dividends

A dividend is paid times per year. Last year, the payout months were and .

PaydateDividend

Is the Supernus Pharmaceuticals Dividend Safe?

Supernus Pharmaceuticals has been increasing the dividend for 0 years.

Over the past 10 years, Supernus Pharmaceuticals has increased it by an annual 0 %.

Over a five-year period, the distribution increased by 0%.

Analysts expect a Dividend Cut of -100% for the current fiscal year.

Dividend Details

Understanding Supernus Pharmaceuticals's Dividend Distributions

Supernus Pharmaceuticals’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Supernus Pharmaceuticals's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Supernus Pharmaceuticals's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Supernus Pharmaceuticals’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Supernus Pharmaceuticals Aktienanalyse

What does Supernus Pharmaceuticals do?

Supernus Pharmaceuticals Inc is an American company specializing in the development, manufacturing, and marketing of pharmaceuticals. The company was founded in 2005 and is headquartered in Rockville, Maryland. Initially, Supernus Pharmaceuticals focused on developing medications for neurological disorders such as epilepsy and ADHD. However, the company has since expanded into other areas of indication such as migraine and Parkinson's disease. The top products of Supernus Pharmaceuticals are the two epilepsy medications, Oxtellar XR and Trokendi XR, both based on a patented technology called "Troxerutin Enriched Osmotic Delivery System" (TREOS). This technology allows for timed release of the active ingredient, resulting in longer duration of action and improved tolerability. Both products are approved in the United States and have proven to be effective and well-tolerated. In addition to Oxtellar XR and Trokendi XR, Supernus Pharmaceuticals has launched other products on the market, including XADAGO for the treatment of Parkinson's disease and Qudexy XR for the treatment of migraine. The company also has a number of compounds in the pipeline currently in various stages of development. The business model of Supernus Pharmaceuticals is based on the development of proprietary technologies and the marketing of novel pharmaceuticals. The company works closely with industry and scientific partners to find innovative solutions to medical challenges. For Supernus Pharmaceuticals, quality is a central component of its business model. The company adheres to strict regulatory requirements and employs modern manufacturing techniques to ensure the highest standards in pharmaceutical production. Additionally, the company maintains close relationships with healthcare providers and patient organizations to ensure that its products meet the needs of patients. Supernus Pharmaceuticals also pursues a robust growth strategy based on exploring new markets and expanding its product portfolio. The company aims to expand its pipeline and develop new technologies to improve the treatment of neurological disorders and promote patient health worldwide. Overall, Supernus Pharmaceuticals is an innovative company distinguished by its commitment to quality and focus on novel solutions in the pharmaceutical industry. The company has established itself as a leading provider of medications for neurological disorders and strives to expand its position in this growing market. Supernus Pharmaceuticals is one of the most popular companies on Eulerpool.com.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Frequently Asked Questions about Supernus Pharmaceuticals stock

How much dividend does Supernus Pharmaceuticals pay?

Over the past 12 months, Supernus Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Supernus Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Supernus Pharmaceuticals?

The current dividend yield of Supernus Pharmaceuticals is .

When does Supernus Pharmaceuticals pay dividends?

Supernus Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Supernus Pharmaceuticals?

Supernus Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Supernus Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Supernus Pharmaceuticals located?

Supernus Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Supernus Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Supernus Pharmaceuticals from 10/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/6/2024.

When did Supernus Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/6/2024.

What was the dividend of Supernus Pharmaceuticals in the year 2023?

In the year 2023, Supernus Pharmaceuticals distributed 0 USD as dividends.

In which currency does Supernus Pharmaceuticals pay out the dividend?

The dividends of Supernus Pharmaceuticals are distributed in USD.

Andere Kennzahlen von Supernus Pharmaceuticals

Our stock analysis for Supernus Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Supernus Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.